Upload
researchinchina
View
214
Download
0
Tags:
Embed Size (px)
DESCRIPTION
Amid the industrial prosperity and favorable policies, China’s production-use plasma volume broke through 4,000 tons and the total lot release volume jumped by 15% year on year to 52.4 million bottles in 2014. By lot release volume, human albumin, human rabies immunoglobulin, human immunoglobulin (ph4) for intravenous injection and tetanus immunoglobulin were the most popular blood products in China in 2014, accounting for 59.8%, 14.6%, 13.6% and 4.1% of the total lot release volume respectively.
Citation preview
China Blood Product Industry
Report, 2015-2018
Apr. 2015
METHODOLOGY
Both primary and secondary research methodologies were used
in preparing this study. Initially, a comprehensive and exhaustive
search of the literature on this industry was conducted. These
sources included related books and journals, trade literature,
marketing literature, other product/promotional literature, annual
reports, security analyst reports, and other publications.
Subsequently, telephone interviews or email correspondence
was conducted with marketing executives etc. Other sources
included related magazines, academics, and consulting
companies.
INFORMATION SOURCES
The primary information sources include Company Reports,
and National Bureau of Statistics of China etc.
STUDY GOAL AND OBJECTIVES
This report provides the industry executives with strategically significant
competitor information, analysis, insight and projection on the
competitive pattern and key companies in the industry, crucial to the
development and implementation of effective business, marketing and
R&D programs.
REPORT OBJECTIVES
To establish a comprehensive, factual, annually updated and cost-effective information base on market size, competition patterns, market segments, goals and strategies of the leading players in the market, reviews and forecasts. To assist potential market entrants in evaluating prospective acquisition and joint venture candidates. To complement the organizations internal competitor information gathering efforts with strategic analysis, data interpretation and insight.To suggest for concerned investors in line with the current development of this industry as well as the development tendency.To help company to succeed in a competitive market, and understand the size and growth rate of any opportunity.
Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080
Phone: +86 10 82600828 Fax: +86 10 82601570 www.researchinchina.com [email protected]
Copyright 2012 ResearchInChina
*
Abstract
Recombinant blood products have developed for many years in foreign countries, but Chinas blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources are the key to the development of Chinese blood product enterprises.
Amid the industrial prosperity and favorable policies, Chinas production-use plasma volume broke through 4,000 tons and the total lot release volume jumped by 15% year on year to 52.4 million bottles in 2014. By lot release volume, human albumin, human rabies immunoglobulin, human immunoglobulin (ph4) for intravenous injection and tetanus immunoglobulin were the most popular blood products in China in 2014, accounting for 59.8%, 14.6%, 13.6% and 4.1% of the total lot release volume respectively.
At the same time, the supply and R & D capabilities of human
blood coagulation factor VIII, human prothrombin complex and other
small products in rigid demand have been intensified in recent
years. In 2014, the lot release volume of the above two products
ascended by 43.9% and 46.3% year on year respectively. Chengdu
Rongsheng, Guangdong Danxia, Yuanda Shuyang, Shanxi Kangbao and
other enterprises obtained clinical approval for their human blood
coagulation factor VIII in 2014.
Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080
Phone: +86 10 82600828 Fax: +86 10 82601570 www.researchinchina.com [email protected]
Copyright 2012ResearchInChina
*
Given stringent requirements on new domestic plasma stations, Shanghai RAAS, China Biologic Products (Shandong Taibang and Guizhou Taibang), Hualan Biological Engineering, Tiantan Biological (including Chengdu Rongsheng) and Yuanda Shuyang which boast abundant capital, powerful R&D strength and rich plasma station resources have become the top five companies in China blood product industry, contributing 61.3% to Chinas production-use plasma volume and 33.6% to Chinas blood product revenue in 2014.
Shanghai RAAS turns to be a Chinese blood product leader through two acquisitions. In 2014, it took over Banghe Pharmaceutical (now known as Zhengzhou RAAS) and TONROL for RMB1.8 billion and RMB4.758 billion separately, so that the blood product varieties of the company increased from 7 to 11, the number of plasma collection stations rose from 12 to 28, and its plasma collection capacity expanded from 400 tons to 900 tons.
China Blood Product Industry Report, 2015-2018 focuses on the
followings:
Market characteristics, operating environments, status quo, etc. of
China blood product industry;
Supply and demand, competitive landscape, import & export,
development forecast, etc. of China blood product industry;
Supply and demand, competitive landscape, etc. of 8 blood product
segments, including human albumin, human immunoglobulin (pH4) for
intravenous injection, blood coagulation factor and tetanus human
immunoglobulin.
Operation, blood product business and development prospects of 12
major Chinese blood product companies.
Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080
Phone: +86 10 82600828 Fax: +86 10 82601570 www.researchinchina.com [email protected]
Copyright 2012ResearchInChina
*
1. Overview of Blood Product Industry
1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features
2. Overview of China Blood Product Industry
2.1 Market Size
2.2 Status Quo
2.3 Supply and Demand
2.3.1 Supply
2.3.2 Demand
2.4 Market Competition
2.5 Operating Environment
2.5.1 International Market
2.5.2 Policy
2.5.3 Domestic Biopharmaceutical Market
2.6 Import and Export
3. Blood Product Market Segments in China
3.1 Human Albumin
3.1.1 Supply and Demand
3.1.2 Competitive Landscape
3.1.3 Development Prospect
3.2 Human Immunoglobulin (pH4) for Intravenous Injection
Table of contents
Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080
Phone: +86 10 82600828 Fax: +86 10 82601570 www.researchinchina.com [email protected]
3.2.1 Supply and Demand
3.2.2Competitive Landscape
3.3 Blood Coagulation Factor VIII
3.3.1 Supply and Demand
3.3.2 Competitive Landscape
3.3.3 Development Prospect
3.4 Hepatitis B Immunoglobulin
3.4.1 Supply and Demand
3.4.2Competitive Landscape
3.5 Human Immunoglobulin
3.5.1 Supply and Demand
3.5.2 Competitive Landscape
3.6 Human Prothrombin Complex
3.6.1 Supply and Demand
3.6.2 Competitive Landscape
3.7 Tetanus Immunoglobulin
3.7.1 Supply and Demand
3.7.2Competitive Landscape
3.8 Human Rabies Immunoglobulin
3.8.1 Supply and Demand
3.8.2 Competitive Landscape
4. Major Chinese Manufacturers
4.1 China Biologic Products Inc. (NASDAQ: CBPO)
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Customers and Suppliers
4.1.5 R & D and Investment
4.1.6 Shandong Taibang Biological Products Co., Ltd.
4.1.7 Guizhou Taibang Biological Products Co., Ltd.
4.1.8 Xi'an Huitian Blood Products Co., Ltd.
4.1.9 Prospect and Forecast
4.2 Hualan Biological Engineering Inc. (002007.SZ)
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 Customers and Suppliers
4.2.6 R & D and Investment
4.2.7 Blood Products
4.2.8 Prospect and Forecast
4.3 Shanghai RAAS Blood Products Co., Ltd. (002252.SZ)
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 Customers and Suppliers
4.3.6 R & D and Investment
4.3.7 Prospect and Forecast
4.4 Beijing Tiantan Biological Products Co., Ltd. (600161.SH)
*
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Customers and Suppliers
4.4.5 Gross Margin
.4.4.6 R & D and Investment
4.4.7 Blood Products (Chengdu Rongsheng Pharmaceutical Co., Ltd.)
4.4.8 Prospect and Forecast
4.5 Zhenxing Biopharmaceutical and Chemical Co., Ltd. (000403.SZ)
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 Customers and Suppliers
4.5.6 R & D and Investment
4.5.7 Blood Products (Guangdong Shuanglin Bio-Pharmacy Co., Ltd.)
4.5.8 Prospect and Forecast
4.6 Jiangxi Boya Bio-Pharmaceutical Co., Ltd. (300294.SZ)
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 Customers and Suppliers
4.6.6 R & D and Investment
Table of contents
Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080
Phone: +86 10 82600828 Fax: +86 10 82601570 www.researchinchina.com [email protected]
4.6.7 Prospect and Forecast
4.7 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.7.1 Profile
4.7.2 Blood Products
4.8 Shanghai Institute of Biological Products Co., Ltd.
4.8.1 Profile
4.8.2 Blood Products
4.9 Shanxi Kangbao Biological Product Co., Ltd.
4.9.1 Profile
4.9.2 Blood Products
4.10 Green Cross
4.10.1 Profile
4.10.2 Blood Products
4.11 Humanwell Healthcare Group Co., Ltd. (600079.SH)
4.11.1 Profile
4.11.2 Operation
4.11.3 Blood Products (Wuhan Zhongyuan Ruide Biological Product Co., Ltd.)
4.12 Walvax Biotechnology Co, Ltd. (300142.SZ)
4.12.1 Profile
4. 12.2 Operation
4.12.3 Blood Products (Hebei Daan Pharmaceutical Co., Ltd.)
5. Summary and Forecast
5.1 Company Analysis
5.2 Forecast
*
Selected Charts
Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080
Phone: +86 10 82600828 Fax: +86 10 82601570 www.researchinchina.com [email protected]
Selected Charts
Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080
Phone: +86 10 82600828 Fax: +86 10 82601570 www.researchinchina.com [email protected]
Selected Charts
Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080
Phone: +86 10 82600828 Fax: +86 10 82601570 www.researchinchina.com [email protected]
Selected Charts
Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080
Phone: +86 10 82600828 Fax: +86 10 82601570 www.researchinchina.com [email protected]
Selected Charts
Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080
Phone: +86 10 82600828 Fax: +86 10 82601570 www.researchinchina.com [email protected]
Selected Charts
Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080
Phone: +86 10 82600828 Fax: +86 10 82601570 www.researchinchina.com [email protected]
You can place your order in the following alternative ways:
Order online at www.researchinchina.comFax order sheet to us at fax number:+86 10 826015703. Email your order to: [email protected]
4. Phone us at +86 10 82600828/ 82601561
Choose type of format
PDF (Single user license) ..2,500 USD
Hard copy .. 2,650 USD
PDF (Enterprisewide license)....... 3,800 USD
Reports will be dispatched immediately once full payment has been received. Payment may be made by wire transfer or credit card via PayPal.
How to Buy
Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080
Phone: +86 10 82600828 Fax: +86 10 82601570 www.researchinchina.com [email protected]
Party A:Name:Address:Contact Person:TelE-mail:FaxParty B:Name:Beijing Waterwood Technologies Co., Ltd (ResearchInChina)Address:Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080Contact Person:Liao YanPhone:86-10-82600828E-mail:[email protected]:86-10-82601570Bank details:Beneficial Name: Beijing Waterwood Technologies Co., LtdBank Name: Bank of Communications, Beijing BranchBank Address: NO.1 jinxiyuan shijicheng,Landianchang,Haidian District,BeijingBank Account No #: 110060668012015061217Routing No # : 332906Bank SWIFT Code: COMMCNSHBJGTitleFormat CostTotal*
About ResearchInChina
ResearchInChina (www.researchinchina.com) is a leading independent provider of China business intelligence. Our research is designed to meet the diverse planning and information needs of businesses, institutions, and professional investors worldwide. Our services are used in a variety of ways, including strategic planning, product and sales forecasting, risk and sensitivity management, and as investment research.
Our Major Activities
Multi-users market reportsDatabase-RICDBCustom ResearchCompany SearchRICDB (http://www.researchinchina.com/data/database.html ), is a visible financial data base presented by map and graph covering global and China macroeconomic data, industry data, and company data. It has included nearly 500,000 indices (based on time series), and is continuing to update and increase. The most significant feature of this base is that the vast majority of indices (about 400,000) can be displayed in map.
After purchase of our report, you will be automatically granted to enjoy 2 weeks trial service of RICDB for free.
After trial, you can decide to become our formal member or not. We will try our best to meet your demand. For more information, please find at www.researchinchina.com
For any problems, please contact our service team at:
Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080
Phone: +86 10 82600828 Fax: +86 10 82601570 www.researchinchina.com [email protected]
RICDB service
*